On the back of a strong multi-quarter run for biotech, buysiders hope a handful of important catalysts from some of the industry's biggest names will continue to attract generalist interest. A steady flow of news from mid-caps, including launches for prostate cancer, obesity and irritable bowel syndrome drugs, also could draw in generalists.

Big cap biotechs with milestones this quarter include Biogen Idec Inc., Celgene Corp. and Gilead Sciences Inc.